NOTICE OF UPGRADE
Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022
SEARCH LISTED COMPANY
Any AUS or NZ company
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
25 April 2025
| Name: | LTR PHARMA LIMITED (LTP) |
| ISIN: | AU0000305294 |
| Date of Listing: | 11 December 2023 |
Stock Exchange Status: (updated daily)
This entity is currently listed and quoted on the Australian Securities Exchange.Legal Status: (updated monthly)
This is a current registered entity, not in any form of external administration to our knowledge.Capital Gains Tax (CGT) Status: (updated at least quarterly)
To crystallise a capital gain or capital loss on your securities in this entity, you are able to sell your securities on-market in the normal manner. If you determine that the market in your securities is illiquid and you still wish to crystallise a capital gain or loss, kindly contact deListed at admin@delisted.com.au for suggestions as to how you might proceed.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
Automic Registry Pty Ltd
Level 5, 191 ST GEORGES TERRACE PERTH WA 6000
Tel : +61 (2) 8072 1400 or 1300 288 664 (within Australia)
RegistryWebsite RegistryEmail
Expand this box to read and print
The suspension of trading in the securities of LTR Pharma Limited will be lifted immediately following the release by LTP of an announcement regarding the results of primary and secondary clinical study results. | 07/06/2024 |
Initial results show SPONTAN achieves rapid absorption and faster onset of action compared to oral PDE5 inhibitors (i.e., vardenafil, sildenafil, tadalafil). SPONTAN's nasal spray technology delivered a similar amount of drug (Cmax) at half the dose of the oral PDE5 and was significantly faster. Better safety profile for SPONTAN compared to oral PDE5 dosing. Positive data results will be used for regulatory filings in key markets. Critical Company milestone showing that SPONTAN could disrupt the global PDE5 market. | 07/06/2024 |
The securities of LTR Pharma Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of LTP, pending the release of an announcement regarding the results of a primary and secondary clinical study | 06/06/2024 |
listed entity carried for record purposes only | 11/12/2023 |
The suspension of trading in the securities of LTR Pharma Limited will be lifted immediately following the release by LTP of an announcement regarding the results of primary and secondary clinical study results. | 07/06/2024 |
Initial results show SPONTAN achieves rapid absorption and faster onset of action compared to oral PDE5 inhibitors (i.e., vardenafil, sildenafil, tadalafil). SPONTAN's nasal spray technology delivered a similar amount of drug (Cmax) at half the dose of the oral PDE5 and was significantly faster. Better safety profile for SPONTAN compared to oral PDE5 dosing. Positive data results will be used for regulatory filings in key markets. Critical Company milestone showing that SPONTAN could disrupt the global PDE5 market. | 07/06/2024 |
The securities of LTR Pharma Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of LTP, pending the release of an announcement regarding the results of a primary and secondary clinical study | 06/06/2024 |
listed entity carried for record purposes only | 11/12/2023 |
Your browser may reflect a date of printing in American format.
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Lee Rodne | Executive Chairman | 11/12/2023 |
| Julian Chick | Independent Director | 11/12/2023 |
| Maja McGuire | Independent Director | 11/12/2023 |
| David Hwang | Company Secretary | 01/04/2025 |
| Elizabeth Spooner | Company Secretary | 01/04/2025 |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| Shelby Coleman | Company Secretary | 11/12/2024 | 01/04/2025 |
| Belinda Cleminson | Company Secretary | 11/12/2024 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2025 Investogain Pty Limited. All rights reserved.
